Integra LifeSciences (NASDAQ:IART) Downgraded by BTIG Research

BTIG Research lowered shares of Integra LifeSciences (NASDAQ:IART) from a neutral rating to a sell rating in a research report sent to investors on Tuesday morning, Marketbeat reports. They currently have $22.00 price target on the life sciences company’s stock.

A number of other research firms have also weighed in on IART. Truist Financial boosted their target price on shares of Integra LifeSciences from $25.00 to $32.00 and gave the stock a hold rating in a report on Tuesday, July 16th. Bank of America reduced their target price on shares of Integra LifeSciences from $42.00 to $26.00 and set an underperform rating on the stock in a report on Tuesday, May 7th. StockNews.com lowered shares of Integra LifeSciences from a buy rating to a hold rating in a report on Monday, May 13th. Morgan Stanley boosted their target price on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an underweight rating in a report on Monday, July 15th. Finally, Wells Fargo & Company lowered shares of Integra LifeSciences from an overweight rating to an equal weight rating and reduced their target price for the stock from $45.00 to $25.00 in a report on Tuesday, May 7th. Four analysts have rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of Hold and a consensus price target of $29.25.

Integra LifeSciences Price Performance

IART stock opened at $24.61 on Tuesday. The company has a 50 day simple moving average of $29.53 and a 200 day simple moving average of $33.40. The stock has a market cap of $1.91 billion, a price-to-earnings ratio of 49.22, a P/E/G ratio of 0.84 and a beta of 1.11. Integra LifeSciences has a 1 year low of $22.36 and a 1 year high of $45.65. The company has a debt-to-equity ratio of 1.17, a current ratio of 3.39 and a quick ratio of 3.35.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Monday, July 29th. The life sciences company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.01. The business had revenue of $418.20 million during the quarter, compared to analysts’ expectations of $413.07 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.71 EPS. Research analysts anticipate that Integra LifeSciences will post 2.47 EPS for the current fiscal year.

Insider Activity

In other news, Chairman Stuart Essig acquired 52,641 shares of Integra LifeSciences stock in a transaction dated Thursday, May 23rd. The shares were bought at an average cost of $28.49 per share, with a total value of $1,499,742.09. Following the purchase, the chairman now owns 487,922 shares in the company, valued at approximately $13,900,897.78. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Signaturefd LLC boosted its stake in Integra LifeSciences by 248.5% during the fourth quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock worth $25,000 after acquiring an additional 415 shares in the last quarter. Blue Trust Inc. boosted its stake in Integra LifeSciences by 100.5% during the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock worth $26,000 after acquiring an additional 444 shares in the last quarter. Hexagon Capital Partners LLC boosted its stake in Integra LifeSciences by 123.3% during the fourth quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock worth $29,000 after acquiring an additional 370 shares in the last quarter. CWM LLC boosted its stake in Integra LifeSciences by 50.8% during the second quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after acquiring an additional 425 shares in the last quarter. Finally, Valley National Advisers Inc. bought a new position in Integra LifeSciences during the first quarter worth $63,000. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.